Therefore, we hypothesized that PSMD1 and PSMD3 are potential targets for anti-cancer therapeutics and that their relevance stretches beyond CML to other types of cancers. The gene discussed is PSMD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.